Company / Shareholders' Equity
Arcturus Therapeutics Holdings Inc. Shareholders' Equity History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$214.0M
FY2025
5-year range
$214.0M / $396.6M
FY2021-FY2025
Trend
-11.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 3 consecutive years, from $397M in FY2022 to $214M in FY2025.
Based on SEC 10-K filings.
$214M in FY2025 with a 5-year CAGR of +73.4%.
Declined from $279M to $214M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -18.6%
- 5-Year CAGR
- +73.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- Arcturus Therapeutics Holdings Inc.'s shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of +73.4%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 11.2% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $214.0M | -11.2% |
| FY2024 | $241.0M | -13.5% |
| FY2023 | $278.5M | -29.8% |
| FY2022 | $396.6M | +73.8% |
| FY2021 | $228.2M | +1572.9% |
| FY2020 | $13.6M | -59.6% |
| FY2019 | $33.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026